Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

NCT ID: NCT05647343

Last Updated: 2024-07-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-31
• Study Completion Date: 2024-04-08

Brief Summary

The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers

Detailed Description

Participants will receive either the investigational drug (ATL-001) or Placebo (inactive substance). Neither the participant nor the Investigator will know to which of these study drug groups each participant has been assigned. In case of an emergency, however, the Investigator can get this information.

After a 30-day Screening period to confirm the eligibility, the prticipants will be treated for 5 days (the treatment period) and followed by 30 days of observation and assessment of treatment outcomes (the follow-up period).

Conditions

Adverse Effect of Drugs and Medicaments in Therapeutic Use

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

ATL-001 0.2 mg/kg vs Placebo

Cohort 1: ATL-001 at 0.2 mg/kg or Placebo (depending on randomization) will be administered during 5 days

Group Type: EXPERIMENTAL

Ciclopirox Olamine Oral

Intervention Type: DRUG

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Placebo

Intervention Type: OTHER

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

ATL-001 0.5 mg/kg vs Placebo

Cohort 2: ATL-001 at 0.5 mg/kg or Placebo (depending on randomization) will be administered during 5 days

Group Type: EXPERIMENTAL

Ciclopirox Olamine Oral

Intervention Type: DRUG

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Placebo

Intervention Type: OTHER

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

ATL-001 1 mg/kg vs Placebo

Cohort 3: ATL-001 at 1 mg/kg or Placebo (depending on randomization) will be administered during 5 days

Group Type: EXPERIMENTAL

Ciclopirox Olamine Oral

Intervention Type: DRUG

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Placebo

Intervention Type: OTHER

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

ATL-001 2 mg/kg vs Placebo

Cohort 4: ATL-001 at 2 mg/kg or Placebo (depending on randomization) will be administered during 5 days

Group Type: EXPERIMENTAL

Ciclopirox Olamine Oral

Intervention Type: DRUG

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Placebo

Intervention Type: OTHER

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

ATL-001 4 mg/kg vs Placebo

Cohort 5: ATL-001 at 4 mg/kg or Placebo (depending on randomization) will be administered during 5 days

Group Type: EXPERIMENTAL

Ciclopirox Olamine Oral

Intervention Type: DRUG

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Placebo

Intervention Type: OTHER

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Interventions

Ciclopirox Olamine Oral

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Intervention Type: DRUG

Placebo

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Healthy male or female subjects 18 to 65 years of age, inclusive

2. Body mass index (BMI) within the range of 18.0 to 33.0 kg/m2, inclusive, and a minimum weight of at least 50.0 and maximum weight of 100.0 kg at Screening

3. Estimated Glomerular Filtration Rate (eGFR) > 90 mL/min/1.73 m2 at Screening

4. Female subjects of childbearing potential must be using and willing to continue using two medically acceptable contraceptive precautions from Screening and for at least 1 month after the last study drug administration. Medically acceptable forms of contraception include sexual abstinence [periodic abstinence (e.g., calendar, ovulation, symptothermal and post-ovulation methods) are not acceptable], combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), intrauterine devices (IUD), intrauterine hormone-releasing systems, and bilateral tubal ligation for subjects

5. Female subjects of non-childbearing potential must be amenorrhoeic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy/salpingo-oophorectomy (as determined by subject medical history)

6. Male subjects of reproductive potential with a partner(s) of childbearing potential must be using and willing to continue using two medically acceptable contraceptive precautions from Screening and for at least 1 month after the last study drug administration. Medically acceptable forms of contraception include abstinence, vasectomy, or male condom for subjects

7. Female subjects must have a negative pregnancy test

8. Must understand and provide written informed consent prior to the initiation of any protocol-specific procedures

9. Must be willing and able to abide by all study requirements and restrictions

Exclusion Criteria

1. Current drug or alcohol dependence (excluding caffeine), based on self-report, including subjects who have been in a drug rehabilitation program

2. Current smoker or a history of using tobacco products within 3 months prior to Screening

3. Clinically significant abnormalities on physical examination, medical history, 12-lead ECG (i.e., QTc > 440 ms for male subjects and > 450 ms for female subjects), vital signs, or laboratory values, as judged by the investigator or designee

4. History or presence of any clinically significant illness (e.g., cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, musculoskeletal, or psychiatric) or any other condition, which in the opinion of the investigator would jeopardize the safety of the subject or the validity of the study results

5. Use of a non-prescription drug within 14 days prior to the first drug administration. Subjects who have taken over-the-counter medication may still be entered into the study, if in the opinion of the investigator or designee, the medication received will not interfere with the study procedures or data integrity or compromise the safety of the subject

6. Use of any prescription medications, recreational drugs, or natural health products (except vitamin or mineral supplements, acceptable forms of birth control, and hormone replacement) within 14 days prior to first drug administration or throughout the study, unless in the opinion of the investigator or designee, the product will not interfere with the study procedures or data integrity or compromise the safety of the subject

7. Use of any medication that interfere with the glucuronidation metabolic pathway within 14 days prior to first drug administration

8. Positive urine drug screen

9. Positive breath alcohol test. If a subject presents with positive breath alcohol test, the subject may be rescheduled at the discretion of the investigator or designee

10. Female subjects who are currently pregnant or lactating or who are planning to become pregnant within 60 days of last study drug administration

11. Known history of allergy or hypersensitivity to any component of the active drug or placebo

12. Positive for Hepatitis B, Hepatitis C, HIV or COVID-19

13. Treatment with any investigational drug within 30 days prior to first drug administration in the treatment phase

14. A subject who, in the opinion of the investigator or designee, is not considered to be suitable and is unlikely to comply with the study protocol for any reason

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Atlas Molecular Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hassman Research Institute, LLC

Berlin, New Jersey, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

ATL001-PI-CEP

Identifier Type: -

Identifier Source: org_study_id